Document Detail


Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT.
MedLine Citation:
PMID:  10856736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This is a summary of reports of presentation made at the American College of Cardiology 49th Scientific Sessions, Anaheim, 12-15 March 2000. Studies with a particular interest for heart failure physicians have been reviewed. OPTIME-CHF: Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure. OPTIME-CHF was a randomised-controlled trial comparing a 48-h infusion of Milrinone or standard therapy in 951 patients recruited over a 2-year period. Patients were excluded if the investigator believed their clinical condition mandated inotropic therapy. Patients were randomised within 48 h of admission for an acute exacerbation of chronic heart failure to receive Milrinone or placebo infision for 48 h. Of the patients 43% were diabetics, 70% were receiving an angiotensin converting enzyme inhibitor, 25% were already on a beta-Blocker, and 34% had atrial fibrillation. There was no significant difference between the two groups in length of hospital stay during the index admission, subsequent readmissions and days in hospital over the following 60 days. Subjective clinical assessment scores were also no different. There was an average admission rate over the next year of one per patient in both groups. However, there was a significant increase in the incidence of sustained hypotension in the Milrinone group, which accounted for all of the increased adverse event rates for the active therapy. The 60-day mortality was 10% in both groups. This and previous trials of the oral formulation of Milrinone have now clearly demonstrated a lack of benefit with Milrinone in either during acute exacerbations of or in stable severe chronic heart failure [Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral Milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.]. Medium sized studies of Milrinone in patients with milder severities of heart failure also suggested an adverse impact on prognosis in the presence or absence of digoxin [DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral Milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-683.]. Whether Milrinone even has a role for the management of a haemodyamic crisis requiring inotropic therapy must also be questioned.
Authors:
S Thackray; K Witte; A L Clark; J G Cleland
Related Documents :
10471456 - The effect of spironolactone on morbidity and mortality in patients with severe heart f...
21046486 - Selective α1-adrenoceptor antagonist (controlled release tablets) in preoperative manag...
2289216 - A comparison of the efficacy and tolerability of enalapril and sustained-release diltia...
19333246 - The incidence and management of tolerance in intrathecal baclofen therapy.
18830566 - Early use of omeprazole benefits patients with acute myocardial infarction.
6328686 - Recurrence of duodenal ulceration in patients on maintenance ranitidine.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of heart failure     Volume:  2     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-08-23     Completed Date:  2000-08-23     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  209-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use
Adrenergic beta-Antagonists / therapeutic use
Amlodipine / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Cardiotonic Agents / therapeutic use
Doxazosin / therapeutic use
Heart Failure / drug therapy*,  mortality
Humans
Milrinone / therapeutic use
Pyridines / therapeutic use
Randomized Controlled Trials as Topic
Thiazepines / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Cardiotonic Agents; 0/Pyridines; 0/Thiazepines; 1J444QC288/Amlodipine; 36NLI90E7T/omapatrilat; JU9YAX04C7/Milrinone; NW1291F1W8/Doxazosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice...
Next Document:  The management of patients with heart failure in France.